{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:07:18Z","timestamp":1793578038366,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-000572"],"award-info":[{"award-number":["INV-000572"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-008335"],"award-info":[{"award-number":["INV-008335"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.vaccine.2024.03.035","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T20:14:30Z","timestamp":1711397670000},"page":"2867-2876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cost-effectiveness and public health impact of typhoid conjugate vaccine introduction strategies in Bangladesh"],"prefix":"10.1016","volume":"42","author":[{"given":"Christopher","family":"Weyant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7181-9254","authenticated-orcid":false,"given":"Yogesh","family":"Hooda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sira Jam","family":"Munira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5407-2005","authenticated-orcid":false,"given":"Nathan C.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3214-3228","authenticated-orcid":false,"given":"Theresa","family":"Ryckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7769-8035","authenticated-orcid":false,"given":"Arif M.","family":"Tanmoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naito","family":"Kanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1645-3789","authenticated-orcid":false,"given":"Jessica C.","family":"Seidman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6411-3459","authenticated-orcid":false,"given":"Denise","family":"Garrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir K.","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy D.","family":"Goldhaber-Fiebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senjuti","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5967-251X","authenticated-orcid":false,"given":"Jason R.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.03.035_b0005","series-title":"Typhoid Fever, Paratyphoid Fever, and Typhoidal Fevers. Mandell, Douglas, and Bennett\u2019s Principles and Practice of Infectious Diseases","first-page":"1365","author":"Andrews","year":"2019"},{"key":"10.1016\/j.vaccine.2024.03.035_b0010","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/cid\/ciy846","article-title":"Progress in typhoid fever epidemiology","volume":"68","author":"Crump","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.035_b0015","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1473-3099(18)30685-6","article-title":"Typhoid and Paratyphoid Collaborators. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017","volume":"19","author":"GBD 2017","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.035_b0020","doi-asserted-by":"crossref","first-page":"e0008036","DOI":"10.1371\/journal.pntd.0008036","article-title":"Population structure and antimicrobial resistance patterns of Salmonella Typhi isolates in urban Dhaka, Bangladesh from 2004 to 2016","volume":"14","author":"Rahman","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2024.03.035_b0025","doi-asserted-by":"crossref","first-page":"e02112-18","DOI":"10.1128\/mBio.02112-18","article-title":"Salmonella enterica Serovar Typhi in Bangladesh: Exploration of genomic diversity and antimicrobial resistance","volume":"9","author":"Tanmoy","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2024.03.035_b0030","article-title":"Typhoid in Bangladesh: challenges, efforts, and recommendations","volume":"80","author":"Salman","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.vaccine.2024.03.035_b0035","first-page":"CD001261","article-title":"Vaccines for preventing typhoid fever","volume":"2018","author":"Milligan","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.vaccine.2024.03.035_b0040","doi-asserted-by":"crossref","first-page":"7848","DOI":"10.1016\/j.vaccine.2007.08.027","article-title":"Typhoid fever vaccines: systematic review and meta-analysis of randomised controlled trials","volume":"25","author":"Fraser","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.035_b0045","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1016\/S1473-3099(18)30350-5","article-title":"Typhoid conjugate vaccines: a new tool in the fight against antimicrobial resistance","volume":"19","author":"Andrews","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.035_b0050","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/civ295","article-title":"Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study","volume":"61","author":"Mohan","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.035_b0055","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/S0140-6736(17)32149-9","article-title":"Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella typhi: a randomised controlled, phase 2b trial","volume":"390","author":"Jin","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.03.035_b0060","article-title":"Evaluation of a typhoid conjugate vaccine introduction program in Navi Mumbai","author":"Luby","year":"2021","journal-title":"India clinicaltrialsgov"},{"key":"10.1016\/j.vaccine.2024.03.035_b0065","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1905047","article-title":"Phase 3 efficacy analysis of a typhoid conjugate vaccine trial in Nepal","volume":"381","author":"Shakya","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.03.035_b0070","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa2035916","article-title":"Safety and efficacy of a typhoid conjugate vaccine in Malawian children","volume":"385","author":"Patel","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.03.035_b0075","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(21)01124-7","article-title":"Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial","volume":"398","author":"Qadri","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.03.035_b0080","unstructured":"Typhoid vaccines: WHO position paper - March 2018 n.d. https:\/\/www.who.int\/publications-detail-redirect\/whio-wer9313 (accessed January 14, 2024)."},{"key":"10.1016\/j.vaccine.2024.03.035_b0085","doi-asserted-by":"crossref","first-page":"e978","DOI":"10.1016\/S2214-109X(22)00119-X","article-title":"Incidence of typhoid and paratyphoid fever in Bangladesh, Nepal, and Pakistan: results of the surveillance for enteric fever in Asia project","volume":"10","author":"Garrett","year":"2022","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2024.03.035_b0090","doi-asserted-by":"crossref","first-page":"S749","DOI":"10.1093\/infdis\/jiab455","article-title":"Life-course approach to vaccination in Bangladesh for meeting the health and health-related sustainable development goals: a commentary","volume":"224","author":"Bhuiyan","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.035_b0095","doi-asserted-by":"crossref","first-page":"S612","DOI":"10.1093\/infdis\/jiab150","article-title":"Comparison of strategies for typhoid conjugate vaccine introduction in India: a cost-effectiveness modeling study","volume":"224","author":"Ryckman","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.035_b0100","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1137\/141000671","article-title":"Julia: a fresh approach to numerical computing","volume":"59","author":"Bezanson","year":"2017","journal-title":"SIAM Rev"},{"key":"10.1016\/j.vaccine.2024.03.035_b0105","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S1473-3099(18)30804-1","article-title":"Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study","volume":"19","author":"Bilcke","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.035_b0110","series-title":"Cost-Effectiveness in Health and Medicine","year":"2016"},{"key":"10.1016\/j.vaccine.2024.03.035_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(22)00114-8","article-title":"Estimating typhoid incidence from community-based serosurveys: a multicohort study","volume":"3","author":"Aiemjoy","year":"2022","journal-title":"The Lancet Microbe"},{"key":"10.1016\/j.vaccine.2024.03.035_b0120","unstructured":"Bondarenko M, Kerr D, Sorichetta A, Tatem A. Census\/projection-disaggregated gridded population datasets, adjusted to match the corresponding UNPD 2020 estimates, for 183 countries in 2020 using Built-Settlement Growth Model (BSGM) outputs 2020."},{"key":"10.1016\/j.vaccine.2024.03.035_b0125","unstructured":"World Bank Group. Bangladesh Data n.d. https:\/\/data.worldbank.org\/country\/bangladesh (accessed October 4, 2022)."},{"key":"10.1016\/j.vaccine.2024.03.035_b0130","unstructured":"Bangladesh Bureau of Statistics. Bangladesh Sample Vital Statistics 2020; 2021."},{"key":"10.1016\/j.vaccine.2024.03.035_b0135","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1093\/cid\/ciy670","article-title":"The impact of vaccination and prior exposure on stool shedding of Salmonella typhi and Salmonella Paratyphi in 6 controlled human infection studies","volume":"68","author":"Gibani","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.035_b0140","series-title":"Financial Express Bureau. Bharat Biotech\u2019s typhoid vaccine receives WHO pre-qualification","year":"2018"},{"key":"10.1016\/j.vaccine.2024.03.035_b0145","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1016\/j.vaccine.2017.05.087","article-title":"Impact and cost-effectiveness of rotavirus vaccination in Bangladesh","volume":"35","author":"Pecenka","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.035_b0150","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1016\/j.vaccine.2015.07.042","article-title":"Estimating the cost of cholera-vaccine delivery from the societal point of view: a case of introduction of cholera vaccine in Bangladesh","volume":"33","author":"Sarker","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.035_b0155","doi-asserted-by":"crossref","first-page":"e101114","DOI":"10.1371\/journal.pone.0101114","article-title":"Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries","volume":"9","author":"Levin","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.03.035_b0160","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1186\/1471-2458-14-670","article-title":"Performance of 21 HPV vaccination programs implemented in low and middle-income countries, 2009\u20132013","volume":"14","author":"Ladner","year":"2014","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2024.03.035_b0165","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1186\/s12889-015-2046-1","article-title":"A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines","volume":"15","author":"Guerrero","year":"2015","journal-title":"BMC Public Health"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2024.03.035_b0170","doi-asserted-by":"crossref","first-page":"B137","DOI":"10.1016\/j.vaccine.2013.01.036","article-title":"Projections of costs, financing, and additional resource requirements for low- and lower middle-income country immunization programs over the decade, 2011\u20132020","volume":"31","author":"Gandhi","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.035_b0175","doi-asserted-by":"crossref","first-page":"S293","DOI":"10.1093\/cid\/ciaa1334","article-title":"Typhoid and Paratyphoid cost of illness in Bangladesh: patient and health facility costs from the surveillance for enteric fever in Asia project II","volume":"71","author":"Mejia","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.035_b0180","doi-asserted-by":"crossref","first-page":"S306","DOI":"10.1093\/cid\/ciaa1335","article-title":"Typhoid and Paratyphoid cost of illness in Nepal: patient and health facility costs from the surveillance for enteric fever in Asia project II","volume":"71","author":"Mejia","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.035_b0185","doi-asserted-by":"crossref","first-page":"S319","DOI":"10.1093\/cid\/ciaa1336","article-title":"Typhoid and Paratyphoid cost of illness in Pakistan: patient and health facility costs from the surveillance for enteric fever in Asia project II","volume":"71","author":"Mejia","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.035_b0190","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: a systematic analysis for the global burden of disease study 2017","volume":"392","author":"Roth","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.03.035_b0195","unstructured":"World health report: 2002; n.d. https:\/\/www.who.int\/publications-detail-redirect\/9241562072 (accessed July 11, 2022)."},{"key":"10.1016\/j.vaccine.2024.03.035_b0200","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1177\/0272989X13492014","article-title":"Linear regression metamodeling as a tool to summarize and present simulation model results","volume":"33","author":"Jalal","year":"2013","journal-title":"Med Decis Making"},{"key":"10.1016\/j.vaccine.2024.03.035_b0205","doi-asserted-by":"crossref","first-page":"S232","DOI":"10.1093\/infdis\/jix598","article-title":"Comparison of strategies and incidence thresholds for Vi conjugate vaccines against typhoid fever: a cost-effectiveness modeling study","volume":"218","author":"Lo","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.035_b0210","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1016\/j.vaccine.2017.05.001","article-title":"Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings","volume":"35","author":"Antill\u00f3n","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.035_b0215","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1016\/j.vaccine.2021.06.003","article-title":"Cost effectiveness of typhoid vaccination in India","volume":"39","author":"Chauhan","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.035_b0220","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.vaccine.2022.12.032","article-title":"Comparison of model predictions of typhoid conjugate vaccine public health impact and cost-effectiveness","volume":"41","author":"Burrows","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.035_b0225","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1093\/ofid\/ofad021","article-title":"Seroepidemiology for enteric fever: Emerging approaches and opportunities","volume":"10","author":"Aiemjoy","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.035_b0230","doi-asserted-by":"crossref","first-page":"S222","DOI":"10.1093\/infdis\/jiy543","article-title":"Case-fatality ratio of blood culture-confirmed typhoid fever in Dhaka","volume":"218","author":"Yu","year":"2018","journal-title":"Bangladesh J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.035_b0235","doi-asserted-by":"crossref","first-page":"e0004926","DOI":"10.1371\/journal.pntd.0004926","article-title":"Using a human challenge model of infection to measure vaccine efficacy: a randomised, controlled trial comparing the typhoid vaccines M01ZH09 with placebo and Ty21a","volume":"10","author":"Darton","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2024.03.035_b0240","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2105\/AJPH.33.3.221","article-title":"Age and sex as factors in the development of the typhoid carrier state, and a method for estimating Carrier prevalence","volume":"33","author":"Ames","year":"1943","journal-title":"Am J Public Health Nations Health"},{"key":"10.1016\/j.vaccine.2024.03.035_b0245","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0140-6736(05)67181-4","article-title":"Typhoid and paratyphoid fever","volume":"366","author":"Bhan","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.03.035_b0250","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.tim.2014.06.007","article-title":"Salmonella chronic carriage: epidemiology, diagnosis, and gallbladder persistence","volume":"22","author":"Gunn","year":"2014","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.vaccine.2024.03.035_b0255","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1056\/NEJM200310023491423","article-title":"Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children","volume":"349","author":"Mai","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.03.035_b0260","unstructured":"UNICEF. Data Warehouse; n.d. https:\/\/data.unicef.org\/resources\/data_explorer\/unicef_f\/ (accessed November 19, 2022)."},{"key":"10.1016\/j.vaccine.2024.03.035_b0265","series-title":"The DHS Program. Demographic and Health Survey 2017-18","article-title":"National Institute of Population Research and Training","year":"2020"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2024.03.035_b0270","doi-asserted-by":"crossref","first-page":"A99","DOI":"10.1016\/j.vaccine.2014.12.037","article-title":"Costs of vaccine programs across 94 low- and middle-income countries","volume":"33","author":"Portnoy","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.035_b0275","doi-asserted-by":"crossref","first-page":"S222","DOI":"10.1093\/cid\/ciaa1320","article-title":"Illness severity and outcomes among enteric fever cases from Bangladesh, Nepal, and Pakistan: data from the surveillance for enteric fever in Asia project, 2016\u20132019","volume":"71","author":"Longley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.035_b0280","series-title":"Bangladesh Bureau of Statistics. Bangladesh Sample Vital Statistics 2017","year":"2018"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24003220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24003220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T04:16:12Z","timestamp":1712981772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24003220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0264410X24003220"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.03.035","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness and public health impact of typhoid conjugate vaccine introduction strategies in Bangladesh","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.03.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}